Condition: Metabolic Dysfunction-Associated Liver Disease · Sponsor: Hospices Civils de Lyon
Type 2 diabetes (T2DM) patients are at high-risk for advanced fibrosis (AF) due to non-alcoholic fatty liver disease (NAFLD), recently renamed Metabolic dysfunction-Associated Liver Disease (MASLD). Thus, patients with T2DM are recognized as a priority target for the screening of MASLD-related advanced fibrosis and a systematic screening for AF is currently recommended in T2DM patients using FIB-4 and liver stiffness measurement (LSM).The main objective of the project is to investigate the ability of baseline non-invasive biomarkers to discriminate patients with a progression of MASLD from patients without progression of MASLD among patients with T2DM and to investigate the association between clinical outcomes related to the natural evolution of MASLD and T2DM and baseline biomarkers.
This description comes directly from the study's public registry record.
Cyrielle CAUSSY, Pr · 4 78 86 44 48 · cyrielle.caussy@chu-lyon.fr
Dominique DELAUNAY, Dr · 4 72 11 00 64 · Dominique.delaunay@chu-lyon.fr
Always discuss trial participation with your own doctor first.
| Service Endocrinologie, Diabétologie, Maladies Métaboliques et Nutrition | Dijon, France | Recruiting |
| Endocrinologie, Diabète et Nutrition in Louis PRADEL Hospital | Lyon, France | Recruiting |
| Clinique d'Endocrinologie, Maladies Métaboliques et Nutrition CIC Endocrino-Nut | Nantes, France | Recruiting |
| Service d'Endocrinologie, Diabète et nutrition | Pierre-Bénite, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06567990